Navigation Links
Medarex Announces July 10 Live Webcast of R&D Day Event
Date:7/7/2008

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) invites investors, the media and the general public to listen to a live webcast of its 2008 R&D Day event. The webcast will begin on Thursday, July 10, 2008 at 8:00 a.m. Eastern Time and is expected to last approximately four hours. Members of Medarex's senior management will provide an overview of the company's strategy, progress and new information about advancements in the research and development pipeline and other ongoing programs.

Interested parties may access the live webcast through the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the event will be available for at least 14 days following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody product
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... The Raymond and Ruth Perelman School ... announces the launching of a first-of-its-kind interdisciplinary center ... The Center will bring together, without institutional walls, ... diseases: establishing dedicated research support facilities, translating findings ...
... 26, 2011 Neogen Corporation (NASDAQ: NEOG ) ... which ended May 31, increased 30% from the previous year ... $0.96 per share, compared to the prior year,s $0.76 per ... 23% to $172,683,000, up from $140,509,000 in the company,s previous ...
... Fla., July 26, 2011 Dyadic International, Inc. (OTC ... it will report its financial results for the second ... Thursday, August 4, 2011 and will host a conference ... financial results. (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO) Those ...
Cached Biology Technology:Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy 2Neogen Reports 30% Increase in Net Income 2Neogen Reports 30% Increase in Net Income 3Neogen Reports 30% Increase in Net Income 4Neogen Reports 30% Increase in Net Income 5
(Date:5/23/2013)... , the team reveal the interplay of brain chemicals ... the Wellcome Trust and BBSRC. , By changing ... our perceptual abilities. While these changes can affect the ... the fidelity of that response. , Lead ... you communicate with others, you can make yourself better ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Tests lead to doubling of fuel cell life 2
... BioMed Central,s premier open access medical journal Genome ... its January 2009 issue. Genomic medicine is at ... of fastest growing areas of biomedical research. Our growing ... it possible to identify the genetic changes that underlie ...
... that contain instructions for making proteins make up less ... reasons, most of our genome is transcribed into RNA. ... are easier to study than humans. Researchers in the ... Laboratory (EMBL) in Heidelberg, Germany, and Wolfgang Huber at ...
... FDA has approved the first human clinical trial of ... but not only, or even primarily, because what is ... Although deep-seated disagreements about the ethics of embryo research ... focus as well on this being the first human ...
Cached Biology News:Genome Medicine: Bridging the gap between research and clinical practice 2Rewrite the textbooks: Transcription is bidirectional 2
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: